Boehringer Ingelheim Advances Oncology Research Boehringer Ingelheim Advances Oncology Research Boehringer Ingelheim Advances Its Oncology Research Program Through Innovative Partnerships
Oncology and Cancer Immunology Research Oncology and Cancer Immunology Research Find out more about our research and development in oncology and cancer immunology.
New cancer research building: Boosting innovation in oncology New cancer research building: Boosting innovation in oncology With our new cancer research building in Vienna, we’ll advance our oncology pipeline and strengthen our commitment to innovation and collaboration.
Groundbreaking oncology research zongertinib Groundbreaking oncology research zongertinib Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
Veterinary oncology experts meet in Germany Veterinary oncology experts meet in Germany Veterinary oncology experts meet prior to the European Society of Veterinary Oncology Congress in Hofheim, Germany
Oncology Oncology We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
Boehringer expands cancer research at Vienna site Boehringer expands cancer research at Vienna site Boehringer Ingelheim expands cancer research at its Vienna site
New exchange platform with Harbin Research Institute New exchange platform with Harbin Research Institute Boehringer Ingelheim and Harbin Veterinary Research Institute set up ‘industry-academia-research’ exchange platform
2020 European PRRS Research Award sponsorship 2020 European PRRS Research Award sponsorship 2020 European PRRS Research Award: Boehringer Ingelheim calls for submissions
Winners of the 2020 European PRRS Research Award Winners of the 2020 European PRRS Research Award Winners of the 2020 European PRRS Research Award announced Three winner awarded 25,000 euro each for their research.
Partnership canine oncology Partnership canine oncology The collaboration will focus on identifying new molecules to target cancers in dogs. Small molecules could provide superior disease control.
2021 PRRS Research Award winners announced 2021 PRRS Research Award winners announced The 2021 European PRRS Research Award winners announced
Research Beyond Borders Partnering Research Beyond Borders Partnering Our Research Beyond Borders team is looking for emerging science and technology opportunities. Learn more about partnering with us.
Winners of the 2019 European PRRS Research Award Winners of the 2019 European PRRS Research Award Winners of the 2019 European PRRS Research Award announced.
Research ruminant animal health well-being Research ruminant animal health well-being Boehringer Ingelheim supports young scientists and veterinarians dedicated to ruminant health research
Immunology Respiratory Research Immunology Respiratory Research Find out more about our research and development in Immunology & Respiratory diseases
Boehringer Ingelheim 2022 half year results Boehringer Ingelheim 2022 half year results First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Research Beyond Borders overview Research Beyond Borders overview Learn more about how our Research Beyond Borders team is uncovering new ideas and new science.
Europe needs a vibrant research eco-system Europe needs a vibrant research eco-system At this week's EFPIA Days in Brussels, stakeholders will discuss how to re-establish a research-friendly eco-system in Europe.
Future Leaders in Veterinary Medicine and Research Future Leaders in Veterinary Medicine and Research Through the Boehringer Ingelheim Veterinary Scholars Program, we offer opportunities for students to gain research experience and explore new career paths.
Boehringer acquires T3 Pharma Boehringer acquires T3 Pharma Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
Acquisition expands research in cancer immunology Acquisition expands research in cancer immunology Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.
Martin Stefanic Martin Stefanic Martin Stefanic, Patient Safety Therapeutic Area Head for Oncology, discusses his move to Patient Safety.